Clinical Trial Goal
To find out:
- The highest dose of LP-118 that’s safe to give
- If LP-118 is safe and works well to treat blood cancer that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following blood cancers that has relapsed or is refractory:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL) with Richter’s transformation
- Chronic myelomonocytic leukemia (CMML)
- Multiple myeloma
- Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN)
- MDS that doctors think is high risk
- Myelofibrosis
- Non-Hodgkin lymphoma (NHL)
- Small lymphocytic lymphoma (SLL)
- T-cell prolymphocytic leukemia (T-PLL)
- Have not had a blood or marrow transplant (BMT) in the last 2 months
- Do not have graft-versus-host disease (GVHD)
- Do not have cancer cells in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
LP-118 is a small molecule inhibitor that blocks BCL-2 in certain cells.
You’ll get:
You’ll get:
- LP-118 – A pill that you take by mouth 1 time each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for about 3 years.
The Food and Drug Administration (FDA) has not yet approved LP-118.
Contacts
Anna Chen, MD, PhD, (206) 335-3820, yu@newavepharma.com
Stephen Anthony, DO, s.anthony@newavepharma.com
Locations
Sponsors
lead: Newave Pharmaceutical Inc
